LAVAL, Quebec, May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 16, 2018 at 10:40 a.m. PDT (1:40 p.m. EDT).

A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at: http://ir.valeant.com/events-and-presentations/2018.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.valeant.com.

Investor Contact:       

Media Contact:

Arthur Shannon                 

Lainie Keller

arthur.shannon@valeant.com    

lainie.keller@valeant.com

(514) 856-3855        

(908) 927-0617

(877) 281-6642 (toll free)       


         

Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/)

                                                                            

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-to-participate-at-2018-bank-of-america-merrill-lynch-healthcare-conference-300645622.html

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2018 PR Newswire

Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Valeant Pharma Charts.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Valeant Pharma Charts.